TTP399: Phase IIa data

TransTech said data from a Phase IIa trial in 128 Type II diabetics on stable doses of metformin showed that TTP399 significantly reduced HbA1c from baseline at week 6 vs. placebo (placebo-corrected reduction of 0.53%, p<0.001). In patients with baseline HbA1c <=7.5%, TTP399 led to target HbA1c levels of <=7% in 100% of patients and target HbA1c levels of <=6.5% in 85% of patients. No patients in the placebo group achieved HbA1c <=6.5%. TransTech said all tested doses of TTP339 were safe. Patients received twice-daily 200, 400 or 800 mg TTP339 or placebo. The company plans to publish the data in a scientific paper, but did not disclose a timeline. Forest Laboratories Inc. (NYSE:FRX, New York, N.Y.) conducted the trial. ...